News About: R&D


Subject of bioequivalence test will be extended to powder and granule

Bioequivalence tests, which have only been conducted on tablets, capsules and suppositories, will be extended to powder and granule products from November 2018. The Ministry of Food and Drug Safety(MFDS) held the ‘Ci...

“It is not required to conduct animal studies for biosimilar development in some countries”

It was observed it was not required to conduct animal studies in the progress of developing biosimilars in some countries. At the ‘Global Bio Conference’ at Intercontinental Coex Seoul on the 29th, Dr. Jian Wang(Heal...

Hanmi’s 3-sbustance combination drug containing Amosartan & rosuvastatin represented at EHS

2 case results of clinical trial for ‘Amosartan,’ a combination drug developed by Hanmi Pharm, were announced at the European Society of Hypertension(ESH). Hanmi Pharm announced on the 20th that it presented a Phase ...

Hanmi Pharm presents study results of LAPSCOVERY at ADA

2 candidate substances of biologic applied with ‘LAPSCOVERY,’ Hanmi Pharm’s own platform technology, were revealed at the world’s largest diabetes association American Diabetes Association(ADA). Hanmi Pharm(CEO Sae-C...

SK Chemicals will jointly carry out development and Phase 3 clinical trial of next generation children enteritis vaccine

SK Chemicals is enlarging its position in the international market with its technology and manufacturing power in vaccine. SK Chemicals announced on the 1st that it signed an agreement for development of a next-gener...

Korea conducts 2nd largest number of clinical trials for stem cell treatments in the world

It was observed Korea became a country that conducted the 2nd highest number of clinical trials for stem cell treatments after the U.S. The Ministry of Food and Drug Safety’s National Institute of Food and Drug Safet...

Oscotec’s FDA-approved clinical trials for treatment of acute myeloid leukemia

Oscotec(CEO Jung-Geun Kim), a new drug development company, announced on the 13th that it made an agreement since the U.S. Phase 1 clinical trial project of the next-generation new drug candidate(SKI-G-801) for the tr...

What will be the answers for future new drug development?

What will be the answers for future new drug development? Celgene chose ‘innovation followed by continuous efforts on new drug development’ and ‘active cooperation with various partners.’ In the lecture about ‘Chang...

Korea advanced in global clinical trials, showing 3.41% market share last year

The number of clinical trials is decreasing, but the Korean clinical trial’s market share in the global market was actually increased by approx. 10% to 3.42%. There were changes in ranking as well because of the China...

R&D chiefs from Korean and overseas pharmas will illustrate present and future of ‘open innovation’

The Korea’s largest ‘Open Innovation’ stage will open for the pharmaceutical industry. The Korea Pharmaceutical and Bio-Pharma Manufacturers Association(Chairman Hee-Mok Won) and the Korean Research-based Pharmaceuti...

TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.